When the DIPG interim data comes out that will be a trigger for either a wind up or a ramp up. The three patients that have been reported on in the 9 piece or by Kazia point towards it being a ramp up. The FDA is wary of approval on small trials, but DIPG is an outlier: no approved therapies, very short fatal disease. My concern is we don't have the brain power to push this point and secure a PRV and early approval. A new management team may be able to do that, but it would require a big cap raise and a huge dilution. Patients and share holders would be better served in selling it to someone that can push for registration and a PRV. The potential brain mets and gbm indications could be captured in an early deal with trailing payments. If DIPG data doesn't point to a PRV, then hold as it falls back to 5c and Hope AGIlE data is good...
- Forums
- ASX - By Stock
- KZA
- KZA Media Thread
KZA Media Thread, page-2047
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online